Seegene Valuation
Is A096530 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A096530?
Other financial metrics that can be useful for relative valuation.
| What is A096530's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | ₩1.34t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | 2.1x |
| PEG Ratio | -0.1x |
Price to Earnings Ratio vs Peers
How does A096530's PE Ratio compare to its peers?
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.5x | ||
A064550 Bioneer | 30.3x | 64.2% | ₩702.0b |
A144510 GC Cell | 13.6x | n/a | ₩703.5b |
A214450 PharmaResearch | 16.3x | 16.9% | ₩757.2b |
A006280 Green Cross | 13.7x | 3.3% | ₩1.5t |
A096530 Seegene | 3.9x | -34.5% | ₩1.3t |
Price-To-Earnings vs Peers: A096530 is good value based on its Price-To-Earnings Ratio (3.9x) compared to the peer average (18.5x).
Price to Earnings Ratio vs Industry
How does A096530's PE Ratio compare vs other companies in the KR Biotechs Industry?
Price to Earnings Ratio vs Fair Ratio
What is A096530's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 3.9x |
| Fair PE Ratio | 10.1x |
Price-To-Earnings vs Fair Ratio: A096530 is good value based on its Price-To-Earnings Ratio (3.9x) compared to the estimated Fair Price-To-Earnings Ratio (10.1x).
Share Price vs Fair Value
What is the Fair Price of A096530 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A096530 (₩27000) is trading above our estimate of fair value (₩17050.52)
Significantly Below Fair Value: A096530 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₩27,000.00 | ₩36,000.00 +33.3% | 6.0% | ₩39,000.00 | ₩34,000.00 | n/a | 3 |
| Jan ’24 | ₩27,200.00 | ₩36,000.00 +32.4% | 6.0% | ₩39,000.00 | ₩34,000.00 | n/a | 3 |
| Dec ’23 | ₩29,750.00 | ₩36,000.00 +21.0% | 6.0% | ₩39,000.00 | ₩34,000.00 | n/a | 3 |
| Nov ’23 | ₩29,050.00 | ₩42,200.00 +45.3% | 4.6% | ₩44,100.00 | ₩39,500.00 | n/a | 3 |
| Oct ’23 | ₩26,800.00 | ₩42,200.00 +57.5% | 4.6% | ₩44,100.00 | ₩39,500.00 | n/a | 3 |
| Sep ’23 | ₩30,750.00 | ₩42,200.00 +37.2% | 4.6% | ₩44,100.00 | ₩39,500.00 | n/a | 3 |
| Aug ’23 | ₩39,100.00 | ₩55,666.67 +42.4% | 3.7% | ₩58,000.00 | ₩53,000.00 | n/a | 3 |
| Jul ’23 | ₩33,900.00 | ₩55,666.67 +64.2% | 3.7% | ₩58,000.00 | ₩53,000.00 | n/a | 3 |
| Jun ’23 | ₩44,450.00 | ₩55,666.67 +25.2% | 3.7% | ₩58,000.00 | ₩53,000.00 | n/a | 3 |
| May ’23 | ₩40,550.00 | ₩81,500.00 +101.0% | 4.3% | ₩85,000.00 | ₩78,000.00 | n/a | 2 |
| Apr ’23 | ₩50,100.00 | ₩81,500.00 +62.7% | 4.3% | ₩85,000.00 | ₩78,000.00 | n/a | 2 |
| Mar ’23 | ₩51,300.00 | ₩81,500.00 +58.9% | 4.3% | ₩85,000.00 | ₩78,000.00 | n/a | 2 |
| Feb ’23 | ₩54,400.00 | ₩81,500.00 +49.8% | 4.3% | ₩85,000.00 | ₩78,000.00 | n/a | 2 |
| Jan ’23 | ₩61,000.00 | ₩79,000.00 +29.5% | 1.3% | ₩80,000.00 | ₩78,000.00 | ₩27,200.00 | 2 |
| Dec ’22 | ₩69,500.00 | ₩79,000.00 +13.7% | 1.3% | ₩80,000.00 | ₩78,000.00 | ₩29,750.00 | 2 |
| Nov ’22 | ₩55,100.00 | ₩84,500.00 +53.4% | 5.3% | ₩89,000.00 | ₩80,000.00 | ₩29,050.00 | 2 |
| Oct ’22 | ₩58,600.00 | ₩84,500.00 +44.2% | 5.3% | ₩89,000.00 | ₩80,000.00 | ₩26,800.00 | 2 |
| Sep ’22 | ₩66,900.00 | ₩112,000.00 +67.4% | 20.5% | ₩135,000.00 | ₩89,000.00 | ₩30,750.00 | 2 |
| Aug ’22 | ₩70,000.00 | ₩116,750.00 +66.8% | 15.6% | ₩135,000.00 | ₩98,500.00 | ₩39,100.00 | 2 |
| Jul ’22 | ₩85,500.00 | ₩116,750.00 +36.5% | 15.6% | ₩135,000.00 | ₩98,500.00 | ₩33,900.00 | 2 |
| Jun ’22 | ₩68,300.00 | ₩153,375.00 +124.6% | 27.8% | ₩215,000.00 | ₩98,500.00 | ₩44,450.00 | 4 |
| May ’22 | ₩93,600.00 | ₩145,800.00 +55.8% | 28.5% | ₩215,000.00 | ₩94,000.00 | ₩40,550.00 | 5 |
| Apr ’22 | ₩67,200.00 | ₩145,900.00 +117.1% | 28.4% | ₩215,000.00 | ₩94,000.00 | ₩50,100.00 | 5 |
| Mar ’22 | ₩62,250.00 | ₩145,900.00 +134.4% | 28.4% | ₩215,000.00 | ₩94,000.00 | ₩51,300.00 | 5 |
| Feb ’22 | ₩89,850.00 | ₩165,280.00 +84.0% | 17.8% | ₩215,000.00 | ₩133,500.00 | ₩54,400.00 | 5 |
| Jan ’22 | ₩96,500.00 | ₩165,280.00 +71.3% | 17.8% | ₩215,000.00 | ₩133,500.00 | ₩61,000.00 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.